These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial. Frishberg Y; Deschênes G; Groothoff JW; Hulton SA; Magen D; Harambat J; Van't Hoff WG; Lorch U; Milliner DS; Lieske JC; Haslett P; Garg PP; Vaishnaw AK; Talamudupula S; Lu J; Habtemariam BA; Erbe DV; McGregor TL; Cochat P; Clin J Am Soc Nephrol; 2021 Jul; 16(7):1025-1036. PubMed ID: 33985991 [TBL] [Abstract][Full Text] [Related]
5. Lumasiran: A Review in Primary Hyperoxaluria Type 1. Kang C Drugs; 2024 Feb; 84(2):219-226. PubMed ID: 38252335 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial. Saland JM; Lieske JC; Groothoff JW; Frishberg Y; Shasha-Lavsky H; Magen D; Moochhala SH; Simkova E; Coenen M; Hayes W; Hogan J; Sellier-Leclerc AL; Willey R; Gansner JM; Hulton SA Kidney Int Rep; 2024 Jul; 9(7):2037-2046. PubMed ID: 39081738 [TBL] [Abstract][Full Text] [Related]
7. Infantile Primary Hyperoxaluria Type 1 Treated With Lumasiran in Twin Males. Aldabek K; Grossman OK; Al-Omar O; Fox JA; Moritz ML Cureus; 2022 Jan; 14(1):e21673. PubMed ID: 35237473 [TBL] [Abstract][Full Text] [Related]
8. Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1. Hulton SA; Groothoff JW; Frishberg Y; Koren MJ; Overcash JS; Sellier-Leclerc AL; Shasha-Lavsky H; Saland JM; Hayes W; Magen D; Moochhala SH; Coenen M; Simkova E; Garrelfs SF; Sas DJ; Meliambro KA; Ngo T; Sweetser MT; Habtemariam BA; Gansner JM; McGregor TL; Lieske JC Kidney Int Rep; 2022 Mar; 7(3):494-506. PubMed ID: 35257062 [TBL] [Abstract][Full Text] [Related]
9. Lumasiran treatment in pediatric patients with PH1: real-world data within a compassionate use program in Italy. Taroni F; Peruzzi L; Longo G; Becherucci F; Malgieri G; D'Alessandro MM; Montini G Clin Kidney J; 2024 May; 17(5):sfae090. PubMed ID: 38742209 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial. Hayes W; Sas DJ; Magen D; Shasha-Lavsky H; Michael M; Sellier-Leclerc AL; Hogan J; Ngo T; Sweetser MT; Gansner JM; McGregor TL; Frishberg Y Pediatr Nephrol; 2023 Apr; 38(4):1075-1086. PubMed ID: 35913563 [TBL] [Abstract][Full Text] [Related]
11. Lumasiran for primary hyperoxaluria type 1: What we have learned? Gang X; Liu F; Mao J Front Pediatr; 2022; 10():1052625. PubMed ID: 36704142 [TBL] [Abstract][Full Text] [Related]
12. Primary hyperoxaluria type 1: novel therapies at a glance. Bacchetta J; Lieske JC Clin Kidney J; 2022 May; 15(Suppl 1):i17-i22. PubMed ID: 35592618 [TBL] [Abstract][Full Text] [Related]
13. Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children. Sas DJ; Magen D; Hayes W; Shasha-Lavsky H; Michael M; Schulte I; Sellier-Leclerc AL; Lu J; Seddighzadeh A; Habtemariam B; McGregor TL; Fujita KP; Frishberg Y; Genet Med; 2022 Mar; 24(3):654-662. PubMed ID: 34906487 [TBL] [Abstract][Full Text] [Related]
14. Case Report: effect of lumasiran treatment in a late preterm baby with antenatal diagnosis of primary hyperoxaluria type 1. Taroni F; Berrettini A; Gnech M; Rella F; Manzoni GA; Montini G Front Pediatr; 2023; 11():1338909. PubMed ID: 38293660 [TBL] [Abstract][Full Text] [Related]
15. Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1. Martin-Higueras C; Borghese L; Torres A; Fraga-Bilbao F; Santana-Estupiñán R; Stefanidis CJ; Tory K; Walli A; Gondra L; Kempf C; Gessner M; Habbig S; Eifler L; Schmitt CP; Rüdel B; Bartram MP; Beck BB; Hoppe B Kidney Int Rep; 2024 Jan; 9(1):114-133. PubMed ID: 38312792 [TBL] [Abstract][Full Text] [Related]
16. New therapeutics for primary hyperoxaluria type 1. Dejban P; Lieske JC Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):344-350. PubMed ID: 35266883 [TBL] [Abstract][Full Text] [Related]
17. Treatment of primary hyperoxaluria type 1. Gupta A; Somers MJG; Baum MA Clin Kidney J; 2022 May; 15(Suppl 1):i9-i13. PubMed ID: 35592620 [TBL] [Abstract][Full Text] [Related]
18. Stiripentol and Lumasiran as a Rescue Therapy for Oxalate Nephropathy Recurrence After Kidney Transplantation in an Adult Patient With Primary Hyperoxaluria Type 1. Lombardi Y; Isnard P; Chavarot N; Chauvet S; Martinez F; Thervet É; Anglicheau D; Karras A Am J Kidney Dis; 2023 Jul; 82(1):113-116. PubMed ID: 36693470 [TBL] [Abstract][Full Text] [Related]
19. A Case Report of Kidney-Only Transplantation in Primary Hyperoxaluria Type 1: A Novel Approach with the Use of Nedosiran. Breeggemann MC; Gluck SL; Stoller ML; Lee MM Case Rep Nephrol Dial; 2023; 13(1):63-69. PubMed ID: 37497389 [TBL] [Abstract][Full Text] [Related]